| Compound | Retatrutide |
|---|---|
| Category | Triple GIP/GLP-1/glucagon receptor agonist |
| Class | GLP-1 and Incretin Therapies |
| Evidence tier | Clinical-stage |
| WADA status | Not individually listed; verify current status if subject to testing |
| Sold on this site | No — this is a reference database |
Overview
Retatrutide is catalogued here as a triple gip/glp-1/glucagon receptor agonist and graded at the "Clinical-stage" evidence tier. This compound has completed or is undergoing formal human trials. Human safety and efficacy are being characterized, but no universal approval exists and results may still fail or be withdrawn.
An investigational triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 results reported some of the largest weight reductions yet seen with an incretin-based agent, and a phase 3 program is ongoing.
Mechanism of Action
Retatrutide combines GLP-1 and GIP receptor activity with glucagon receptor agonism. The glucagon component is hypothesized to add effects on energy expenditure and hepatic lipid handling, though how the three mechanisms combine in humans is still being characterized.
Research and Evidence
In a phase 2 dose-ranging trial (n=338), the highest dose produced a mean weight reduction of approximately 17.5% at 24 weeks, with continued loss through 48 weeks. Phase 3 trials across obesity and type 2 diabetes are underway; it is not an approved medicine anywhere.
Safety and Side Effects
Reported adverse effects in trials have been dominated by dose-related gastrointestinal symptoms. Longer-term safety, gallbladder and pancreatitis risk, and appropriate contraindications remain under investigation — one reason it remains investigational rather than approved.
Frequently Asked Questions
What is the evidence tier of Retatrutide?
Retatrutide is graded "Clinical-stage" on this site. This compound has completed or is undergoing formal human trials. Human safety and efficacy are being characterized, but no universal approval exists and results may still fail or be withdrawn.
Is Retatrutide an approved medicine?
No. Clinical-stage means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.
Where can I read the primary studies for Retatrutide?
The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.
References
- ClinicalTrials.gov — registered retatrutide studies. [source]
- Newman JC, et al. Retatrutide phase 2 results. N Engl J Med 2023 (see trial record for details). [source]
Evidence tier: Clinical-stage · Last reviewed: 2026-09-05 · Sources cited below.